| Literature DB >> 33828866 |
Antonio D'Arienzo1, Edoardo Ipponi1, Alfio Damiano Ruinato1, Silvia De Franco1, Simone Colangeli1, Lorenzo Andreani1, Rodolfo Capanna1.
Abstract
Proximal humerus is one of the anatomical sites that are most frequently involved by bone and soft tissue malignant tumors. Alone or in association with adjuvant treatments, surgery represents the main therapeutic option to treat and eradicate these diseases. Once the first-line option, in the last decades, amputation lost its role as treatment of choice for the large majority of cases in favor of the modern limb sparing surgery that promises to preserve anatomy and-as much as possible-upper limb functionality. Currently, the main approaches used to replace proximal humerus after a wide resection in oncologic surgery can be summarized in biological reconstructions (allografts and autografts), prosthetic reconstructions (anatomic endoprostheses, total reverse shoulder prostheses), and graft-prosthetic composite reconstructions. The purpose of this overview is to present nowadays surgical options for proximal humerus reconstruction in oncological patients, with their respective advantages and disadvantages.Entities:
Year: 2021 PMID: 33828866 PMCID: PMC8004366 DOI: 10.1155/2021/5559377
Source DB: PubMed Journal: Adv Orthop ISSN: 2090-3464
Summary data for allograft studies.
| Study | Resection (cm) | Reconstruction |
| Age (y) | F-U (m) | Hardware issues | Graft resorptions | Fractures | Infections | PSA | Failures | MSTS score |
|
| ||||||||||||
| DeGroot et al. [ | 12 | Osteoarticular allograft | 32 | 30 | 64 | 3% (1) | 0 | 37% (11) | 1 | 16% (5) | 22% (7) | 22.4 |
| Jamshidi et al. [ | 15 | Osteoarticular allograft | 32 | 27 | 46 | 0 | 11% (4) | 8% (3) | 8% (3) | 6% (2) | 22% (8) | 25.5 |
| Mourikis et al. [ | — | Osteoarticular allograft | 32 | 42 | 192 | 0 | 0 | 19% (6) | 13% (4) | 16% (5) | 33% (10) | — |
| Ogink et al. [ | 14 | Osteoarticular allograft | 32 | 47 | — | 6% (3) | 2% (1) | 28% (13) | 4% (2) | 13% (6) | 23% (11) | — |
| Potter et al. [ | 15 | Osteoarticular allograft | 32 | 36 | 24 | 0% | 0% | 53% (9) | 12% (2) | 6% (1) | 29% (5) | 21.3 |
| Rödl et al. [ | 16 | Osteoarticular allograft | 32 | 20 | 59 | 0 | 0 | 18% (3) | 0 | 6% (1) | 12% (2) | 22.2 |
| van de Sande et al. [ | 15 | Osteoarticular allograft | 32 | 34 | 228 | 0 | 0 | 23% (3) | 8% (1) | 15% (2) | — | 22.8 |
| Yao et al. [ | 23 | Osteoarticular allograft/TBIR | 32 | 19 | 62 | 0 | 77% (10) | 38% (5) | 8% (1) | 23% (3) | 38% (5) | — |
N, patients' number; F-U, follow-up; PSA, pseudoarthrosis (nonunion/severe union delay). Data referring to the whole population of the study, in which allografts are only a subpopulation.
Figure 1A FVFG (free vascularized fibular graft) is used to replace proximal humerus in a young growing patient who underwent massive resection to treat a malignant bone tumor. The proximal growing plate of the fibula allowed the autograft to increase its length, mimicking the growth of the native proximal humerus.
Summary data for autograft studies.
| Study | Resection (cm) | Graft type |
| Age (y) | F-U (m) | Hardware issues | Fractures | Infections | PSA | Failures | MSTS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kumar et al. [ | 14 | (Arthrodesis) FVFG | 4 | 24 | 51 | 4% (1) | 0 | 4% (1) | 0 | 0 | — |
| Mimata et al. [ | — | (Arthrodesis) FVFG | 5 | 21 | 75 | 0 | 40% (2) | 0 | 0 | 0 | 21.4 |
| Bilgin [ | — | FVFG | 9 | 38 | 60 | 22% (2) | 11% (1) | 11% (1) | 0 | 0 | 24 |
| Manfrini et al. [ | 13 | FVFG | 11 | 5 | 110 | 0 | 64% (7) | 9% (1) | 22.9 | ||
| Wada et al. [ | 20 | FVFG | 8 | 27 | 70 | 0 | 0 | 0 | 12% (1) | 12% (1) | 23.7 |
| Li et al. [ | — | Allograft + FVGF | 6 | 16 | 19 | 0 | 0 | 0 | 0 | 0 | 28 |
| Liu et al. [ | — | TBIR + FVFG | 16 | 32 | 62 | 0 | 6% (1) | 0 | 25% (4) | 25% (4) | 19 |
| Amin and Ebeid [ | 14 | Scapular pillar autograft | 16 | 21 | 36 | 0 | 0 | 0 | 12% (2) | 12% (2) | 22.5 |
| Padiolleau et al. [ | 12 | Scapular pillar autograft | 12 | 36 | 59 | 0 | 0 | 0 | 25% (3) | 25% (3) | 21.3 |
| Barbier et al. [ | 9 | CPH autograft | 7 | 8–18 | 40 | 14% (1) | 29% (2) | 0 | 71% (5) | 71% (5) | 21.7 |
| Calvert et al. [ | 14 | CPH autograft | 4 | 6 | 43 | 0 | 0 | 0 | 50% (2) | 50% (2) | 26-27 |
| Kitagawa et al. [ | — | CPH autograft | 7 | 29 | 18 | 0 | 0 | 0 | 0 | 0 | 21.5 |
| Rödl et al. [ | — | CPH autograft | 15 | 18 | 59 | 0 | 22% (4) | 22% (4) | 22% (4) | 22% (4) | 24.6 |
| Tsukushi et al. [ | — | CPH autograft | 7 | 36 | 26 | 14% (1) | 0 | 0 | 0 | 0 | 20.7 |
N, patients' number; F-U, follow-up; PSA, pseudoarthrosis (nonunion/severe union delay); FVFG, free vascularized fibular graft; CPH, clavicula pro humero.
Figure 2Anatomic megaprosthesis of proximal humerus implanted in our institution after massive bone resection due to resection of a malignant bone tumor.
Summary data for prosthetic studies.
| Study | Resection (cm) | Prosthesis type |
| Age (y) | F-U (m) | Aseptic loosening | Nerve injury | Instability | Infections | Scapular notching | Reinterventions | Failure | MSTS score | Active ROM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Angelini et al. [ | 11.0 | EndoPT (M) | 33 | 46 | 94 | 2% (1) | 0 | 15% (8) | 4% (2) | — | 35% (19) | 22% (12) | 25 | — |
| Asavamongkolkul et al. [ | — | EndoPT (CM/M) | 33 | 33 | 81 | 3% (2) | 0 | 10% (6) | 3% (2) | — | 20% | 7% (4) | 22.8 | — |
| Cannon et al. [ | 14 | EndoPT (CM/M) | 83 | 55 | 30 | 0 | 0 | 6% (5) | 2% (2) | — | 1% (1) | 1% (1) | 18.9 | Flex42° |
| Fuhrmann et al. [ | — | EndoPT (M) | 21 | 57 | 47 | 0 | 0 | 0 | 5% (1) | — | 9% (2) | 0% | 18 | — |
| Kiss et al. [ | — | EndoPT (M) | 36 | 42 | 56 | 0 | 6% (2) | 25% (9) | 3% (1) | — | 6% (2) | 6% (2) | 19.7 | — |
| Liu et al. [ | 11 | EndoPT (CM) | 25 | 30 | 55 | 36% (9) | 0 | 0 | 0 | — | 36% (9) | 36% (9) | 19.1 | — |
| Manfrini et al. [ | 15.3 | EndoPT (M) | 25 | 10 | 53 | 12% (3) | 0 | 0 | 12% (3) | — | 24% (6) | 16% (4) | 20.9 | — |
| Raiss et al. [ | 13 | EndoPT (M) | 39 | 60 | 38 | 3% (1) | 0 | 10.2% (4) | 5% (2) | — | 12% (5) | 10% (4) | 19 | Flex34° |
| Rödl et al. [ | 17 | EndoPT (M) | 19 | 37 | 59 | 0 | 0 | 0 | 0 | — | 0 | 0 | 23.6 | — |
| Potter et al. [ | 13.6 | EndoPT (M) | 16 | 54 | 34 | 0 | 0 | 19% (3) | 0 | — | 25% (4) | 25% (4) | 20.7 | — |
| van de Sande et al. [ | 9.6 | EndoPT (M) | 14 | 45 | 120 | 0 | 0 | 7% (1) | 0 | — | 7% (1) | 7% (1) | 23.1 | — |
| Wei et al. [ | 20.6 | EndoPT (M) | 20 | 24 | 40 | 10% (2) | 15% (3) | 5% (1) | 0 | — | 5% (1) | 5% (1) | 21.5 | — |
| Bonnevialle et al. [ | 10.5 | Reverse shoulder (P) | 10 | 55 | 42 | 0 | 10% (1) | 30% (3) | 0 | 30% (3) | 20% (2) | 10% (1) | 20.2 | Flex122° |
| De Wilde et al. [ | — | Reverse shoulder (P) | 4 | 42 | 38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27–29 | Flex169° |
| De Wilde et al. [ | — | Reverse shoulder (P) | 14 | 45 | 92 | 1 | 0 | 2 | 1 | 29% (4) | 14% (2) | 14% (2) | — | Abd157° |
| Griffiths et al. [ | — | Reverse shoulder (P) | 42 | 46 | 71 | 0 | 0 | 26% (14) | 5% (2) | 0 | 9% (4) | 0% | 21.7 | — |
| Guven et al. [ | 10.2 | Reverse shoulder (P) | 10 | 49 | 18 | 0 | 0 | 20% (2) | 0 | 20% (2) | 20% (2) | 0% | 23.4 | Flex96° |
| Hu et al. [ | 11.8 | Reverse shoulder (P) | 7 | 35 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25.7 | Flex133 |
| Kaa et al. [ | 11 | Reverse shoulder (P) | 15 | 42 | 46 | 13% (2) | 0 | 7% (1) | 7% (1) | 0 | 27% (4) | 20% (3) | 23 | Flex98° |
| Maclean et al. [ | 9.3 | Reverse shoulder (P) | 8 | 49 | 43 | 12% (1) | 12% (1) | 0 | 0 | 12% (1) | 0% | 0% | 18 | Flex71° |
| Streitbuerger et al. [ | 15.1 | Reverse shoulder (P) | 18 | 42 | 34 | 0 | 0 | 22% (4) | 6% (1) | 0 | 6% (1) | 6% (1) | 25.1 | Flex84° |
N, patients' number; F-U, follow-up. Data referring to the whole population of the study, in which prostheses are only a subpopulation.
Figure 3Reverse shoulder megaprosthesis implanted in our institution after massive bone resection due to resection of a malignant bone tumor.
Summary data for APC studies.
| Study | Malawer classification | Reconstruction type | Ce. |
| Age (y) | F-U (m) | Aseptic loosening | Fractures | Instability | Infections | PSA | Total failures | MSTS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdeen and Healey [ | — | Allograft + EndoPT | No | 36 | — | 60 | 8% (3) | 0 | 3% (1) | 0 | 11% (4) | 19% (7) | Lower in extra articular resection |
| Black et al. [ | 1A | Allograft + EndoPT | Yes | 6 | 41 | 55 | 0 | 0 | 0 | 0 | 17% (1) | 33% (2) | 69% (21) |
| El Beaino et al. [ | 1A | Allograft − EndoPT | Yes | 21 | 41 | 97 | 14% (3) | 5% (1) | 57% (12) (1 rev.) | 5% (1) | 48% (10) | 10% at 5 y FU | 78% (23) |
| King et al. [ | 1A | Allograft + RSR | Yes | 2 | 31 | 51 | 0 | 0 | 0 | 0 | 100% (2) | 100% (2) | — |
| Lazerges et al. [ | 1A | Allograft + RSR | Yes | 6 | 66 | 71 | 0 | 0 | 17% (1) | 0 | 17% (1) | 17% (1) | 73% (22) |
| Moran and Stalley [ | 1B | Allograft + EndoPT | No | 11 | 22 | 70 | 0 | 0 | 36% (4) (3 rev.) | 0 | 18% (2) | 54% (6) | 66% (20) |
| Ruggieri et al. [ | 1A | Allograft + resurface | Yes | 14 | 35 | 25 | 0 | 21% (3) | 0 | 7% (1) (rev.) | 0 | 21% (3) | 77% (23) |
| Sanchez-Sotelo et al. [ | — | Allograft ± RSR | Yes | 26 | 62 | 48 | 0 | 8% (2) | 4% (1) | 4% (1) | 11% (3) | 23% (6) | — |
| Potter et al. [ | — | Allograft + EndoPT | Yes | 16 | 56 | 24 | 0 | 6% (1) | 19% (3) | 13% (2) | 6% (1) | 6% (1) | 79% (24) |
| van de Sande et al. [ | IA | Allograft + EndoPT | Yes | 10 | 34 | 204 | 0 | 20% (2) | 40% (4) | 20% (2) | 30% (3) | 30% (3) | 72% (22) |
Ce, cement; N, patients' number; F-U, follow-up; PSA, pseudoarthrosis (nonunion/severe union delay).
Figure 4Schematic summary of the main advantages and disadvantages, with consequential indications, for the main reconstructive approaches to proximal humerus in oncologic surgery.